-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Kang Enbei issued an announcement stating that the transfer of 42% of the shares of the subsidiary Cherish Ming, the current consortium consisting of five companies including Zhongsheng Pharmaceutical will be transferred with a total consideration of 1.
68 billion yuan
.
Specifically, on December 2, Conba received the "Listing Project Information Feedback Letter" issued by the Zhejiang Equity Exchange.
After the initial review of the bidding materials submitted by the intended transferee by the Zhejiang Equity Exchange, it complies with the transaction regulations The intended transferee is a consortium consisting of five companies: Fortunate Gem Limited, Huagai Xincheng Yuanhang, Anhui Traffic Holdings Jinshi Fund, Hainan Yuemu Minhan, and Zhongsheng Pharmaceutical.
Let Zhenshiming's 30%, 4.
75%, 4%, 2.
5%, and 0.
75% of the shares of Zhenshiming, and transfer a total of 42% of the shares of Zhenshiming.
The transaction amount is estimated to be RMB 1.
68 billion
.
Public information shows that in the first half of this year, Cherish Ming’s revenue was 509 million, and its contribution to Conba’s revenue was second only to the "Changyanning" series of products.
In the same period, Cherish Ming’s net profit was close to 70 million, accounting for nearly three of the net profit of Kang Enbei’s return to mothers.
One part
.
From the overall point of view, the importance of cherishing the Ming can be said to be self-evident
.
However, this time Kang Enbei still decided to "break away".
According to the announcement, the main purpose is to focus on the core business of the traditional Chinese medicine health industry and promptly dispose of inefficient assets and withdraw funds
.
It is reported that after preliminary calculations, if the equity transfer is completed at the listed reserve price, it is expected to increase Conba’s net profit by approximately 2.
3 billion yuan, which will have a significant positive impact on Conba’s performance
.
It is worth noting that since this year, Conba has been busy selling equity and assets in order to release equity pledges, focus on core businesses, promptly dispose of inefficient assets, and withdraw funds; it is reported that Conba has already sold shares before this transaction.
After transferring the equity of a number of holding companies
.
For example, on November 29, Kang Enbei issued an announcement stating that it would publicly transfer 25% of the shares of Dear Pharmaceuticals
.
The content of the announcement shows that the transfer is to focus on the development of the company’s core business of the traditional Chinese medicine health industry, timely disposal of inefficient assets, and withdrawal of funds.
Zhejiang Jinhua Kangenbei Biopharmaceutical Co.
, Ltd.
"Bei") intends to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Dear Pharmaceutical") held by Zhejiang Equity Exchange through public listing
.
According to the assessment, the assessed value of Jinhua Kangenbei's 25% equity stake in Dier Pharmaceutical is RMB 39,747,228.
58
.
On August 13, Kang Enbei issued an announcement stating that the board of directors agreed to the company’s transfer of 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; a supplementary announcement was issued on November 6 stating that the initial listing period had not expired.
Intentional transferees who have solicited equity
.
On June 12, Conba Pharmaceutical Co.
, Ltd.
intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
, Ltd.
held by the Zhejiang Equity Exchange through a public listing.
The transfer was completed at a price of 53.
37 million yuan.
Let, on October 28, complete the registration procedures for industrial and commercial changes
.
In addition, in addition to the transfer of equity, Conba has actually released a number of pledges and returned the raised funds recently
.
In this regard, the industry believes that Conba’s move to revitalize funds through the transfer has achieved results
.
68 billion yuan
.
Specifically, on December 2, Conba received the "Listing Project Information Feedback Letter" issued by the Zhejiang Equity Exchange.
After the initial review of the bidding materials submitted by the intended transferee by the Zhejiang Equity Exchange, it complies with the transaction regulations The intended transferee is a consortium consisting of five companies: Fortunate Gem Limited, Huagai Xincheng Yuanhang, Anhui Traffic Holdings Jinshi Fund, Hainan Yuemu Minhan, and Zhongsheng Pharmaceutical.
Let Zhenshiming's 30%, 4.
75%, 4%, 2.
5%, and 0.
75% of the shares of Zhenshiming, and transfer a total of 42% of the shares of Zhenshiming.
The transaction amount is estimated to be RMB 1.
68 billion
.
Public information shows that in the first half of this year, Cherish Ming’s revenue was 509 million, and its contribution to Conba’s revenue was second only to the "Changyanning" series of products.
In the same period, Cherish Ming’s net profit was close to 70 million, accounting for nearly three of the net profit of Kang Enbei’s return to mothers.
One part
.
From the overall point of view, the importance of cherishing the Ming can be said to be self-evident
.
However, this time Kang Enbei still decided to "break away".
According to the announcement, the main purpose is to focus on the core business of the traditional Chinese medicine health industry and promptly dispose of inefficient assets and withdraw funds
.
It is reported that after preliminary calculations, if the equity transfer is completed at the listed reserve price, it is expected to increase Conba’s net profit by approximately 2.
3 billion yuan, which will have a significant positive impact on Conba’s performance
.
It is worth noting that since this year, Conba has been busy selling equity and assets in order to release equity pledges, focus on core businesses, promptly dispose of inefficient assets, and withdraw funds; it is reported that Conba has already sold shares before this transaction.
After transferring the equity of a number of holding companies
.
For example, on November 29, Kang Enbei issued an announcement stating that it would publicly transfer 25% of the shares of Dear Pharmaceuticals
.
The content of the announcement shows that the transfer is to focus on the development of the company’s core business of the traditional Chinese medicine health industry, timely disposal of inefficient assets, and withdrawal of funds.
Zhejiang Jinhua Kangenbei Biopharmaceutical Co.
, Ltd.
"Bei") intends to transfer the 25% equity of Zhejiang Dier Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Dear Pharmaceutical") held by Zhejiang Equity Exchange through public listing
.
According to the assessment, the assessed value of Jinhua Kangenbei's 25% equity stake in Dier Pharmaceutical is RMB 39,747,228.
58
.
On August 13, Kang Enbei issued an announcement stating that the board of directors agreed to the company’s transfer of 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; a supplementary announcement was issued on November 6 stating that the initial listing period had not expired.
Intentional transferees who have solicited equity
.
On June 12, Conba Pharmaceutical Co.
, Ltd.
intends to transfer the 30% equity of Lanxi City Lanxin Small Loan Co.
, Ltd.
held by the Zhejiang Equity Exchange through a public listing.
The transfer was completed at a price of 53.
37 million yuan.
Let, on October 28, complete the registration procedures for industrial and commercial changes
.
In addition, in addition to the transfer of equity, Conba has actually released a number of pledges and returned the raised funds recently
.
In this regard, the industry believes that Conba’s move to revitalize funds through the transfer has achieved results
.
